Biological product manufacturing standards
Executive Summary
FDA issues final rule establishing general requirements for cell lines used for manufacturing any biological product for human use. The rule, in the Dec. 10 Federal Register, requires manufacturers to describe in their applications the tumorigenic potential of a cell line. Since the general requirements apply to all biological products, the specific requirements for poliovirus vaccine live oral under an existing regulation are no longer necessary. FDA notes that the requirements do not pertain to primary cell cultures that are not subcultivated and primary cell cultures that are subcultivated for only a very limited number of population doublings.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.